DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
  • Stocks
  • /
  • Pharmaceuticals & Biotech
Updated 1d ago
6955 logo

Bonraybio Co., Ltd.TWSE:6955 Stock Report

Market Cap NT$2.9b
Updated 1d ago
Share Price
n/a
1Y-30.9%
7D-4.0%
1D-1.0%
Portfolio Value
​
View

Bonraybio Co., Ltd.

TWSE:6955 Stock Report

Market Cap: NT$2.9b

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Bonraybio (6955) Stock Overview

A development stage company, manufactures medical instruments and solutions for the male infertility market. More details

6955 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends2/6

Rewards

Price-To-Earnings ratio (26.7x) is below the Biotechs industry average (27.2x)

Earnings grew by 27.8% over the past year

Risk Analysis

High level of non-cash earnings

Does not have a meaningful market cap (NT$3B)


6955 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW430,343 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
430,343 investors already sharing narratives
NT$
Current Price
NT$95.0030.8% overvalued intrinsic discount
%/yr
Decrease
Increase
PastFuture-36m332m2016201920222025202620282031Revenue NT$332.2mEarnings NT$108.0m
Advanced
View all narratives

Bonraybio Co., Ltd. Competitors

Maxigen Biotech

Symbol: TWSE:1783
Market cap: NT$3.3b

Allied Biotech

Symbol: TPEX:1780
Market cap: NT$2.7b

3D Global Biotech

Symbol: TPEX:6808
Market cap: NT$2.4b

Pet Pharm Biotech

Symbol: TPEX:7762
Market cap: NT$3.2b

Price History & Performance

Summary of share price highs, lows and changes for Bonraybio
Historical stock prices
Current Share PriceNT$95.00
52 Week HighNT$144.49
52 Week LowNT$88.98
Beta0.097
1 Month Change-2.62%
3 Month Change-9.08%
1 Year Change-30.93%
3 Year Change86.78%
5 Year Changen/a
Change since IPO78.13%

Recent News & Updates

Recent updates

Shareholder Returns

6955TW BiotechsTW Market
7D-4.0%-1.0%2.3%
1Y-30.9%78.4%82.2%

Return vs Industry: 6955 underperformed the TW Biotechs industry which returned 78.4% over the past year.

Return vs Market: 6955 underperformed the TW Market which returned 82.2% over the past year.

Price Volatility

Is 6955's price volatile compared to industry and market?
6955 volatility
6955 Average Weekly Movement4.4%
Biotechs Industry Average Movement6.5%
Market Average Movement5.7%
10% most volatile stocks in TW Market11.0%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 6955 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 6955's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/aZhenteng Xubonraybio.com

Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also provides consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes.

Bonraybio Co., Ltd. Fundamentals Summary

How do Bonraybio's earnings and revenue compare to its market cap?
6955 fundamental statistics
Market capNT$2.89b
Earnings (TTM)NT$107.98m
Revenue (TTM)NT$332.21m
26.7x
P/E Ratio
8.7x
P/S Ratio

Is 6955 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6955 income statement (TTM)
RevenueNT$332.21m
Cost of RevenueNT$75.18m
Gross ProfitNT$257.03m
Other ExpensesNT$149.05m
EarningsNT$107.98m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)3.55
Gross Margin77.37%
Net Profit Margin32.50%
Debt/Equity Ratio0%

How did 6955 perform over the long term?

See historical performance and comparison

Dividends

1.3%
Current Dividend Yield
34%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/20 01:33
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bonraybio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide